Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance.
According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment.
"At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health."
Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles.
"Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication."
Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity.
For more information or to access the GoodRx Contrave savings card, visit: https://www.goodrx.com/contrave. *Program benefit maximums and eligibility restrictions may apply.
About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit www.curraxpharma.com.
About CONTRAVE:
CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to www.CONTRAVE.com.
Media Contactcurrax@ampublicrelations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/currax-expands-access-to-fda-approved-obesity-treatment-with-brand-name-contrave-with-new-cash-price-available-via-goodrx-302505664.html
SOURCE Currax Pharmaceuticals LLC
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Geographic
23 minutes ago
- National Geographic
Forget about 10,000 steps a day—science now has a more accurate number
Walking more is associated with reduced risk for dementia, diabetes, heart disease, and more—but a new study says you can get fewer than 10,000 steps a day and still see all those benefits. An explorer walks across sand dunes on Socotra, Yemen, 2018. Getting 10,000 steps in every day can be challenging, and a new study suggests 7,000 steps can reduce the risk of developing common but serious health conditions. Photograph by Martin Edstrom, Nat Geo Image Collection If you've been told that walking 10,000 steps a day is mandatory for good health, you might be surprised to learn that scientists suspect the figure was created to market pedometers and wasn't based on actual data. The number of steps that stave off numerous chronic conditions is actually much lower, according to a paper published today in Lancet Public Health that reviewed the past decade's research on steps and health. Walking just 7,000 steps a day lowers the risk of developing more than a half dozen medical conditions as well as premature death, according to the researchers. The scientists, from Australia, the United Kingdom, and Norway, analyzed dozens of studies involving 160,000 adults putting one foot in front of the other. Compared to people walking 2,000 steps, the 7,000-step total was associated with a 38 percent lower risk of dementia, a 25 percent reduction in cardiovascular disease, and 28 percent fewer falls. Mortality dropped nearly half in the 7,000-step walkers. Risks for depression and type 2 diabetes also fell, although by less than for the other conditions. It's long been known that physical activity, including moderate-intensity walking, benefits health. But this is the first time researchers were able to correlate step goals with the wide range of preventive health outcomes. 'Step counting devices are becoming so widely available that the general public wants to know what they should aim for,' says Melody Ding, a public health researcher at the University of Syndey in Australia and the study's lead author. People can now feel confident with a target of 7,000, she says. How more research led to a more accurate estimate This study 'is really exciting because it looks at how step volume makes a big difference in several major health outcomes,' says Michael Rocha, a cardiologist in Dartmouth, Massachusetts who leads walking excursions in his community as part of the nationwide Walk with a Doc health program. 'We now have more evidence to change what we are telling our patients. It doesn't have to be 10,000 a day to live longer and healthier,' he says. As recently as 2020, scientists formulating physical activity guidelines for Americans as well as for a global audience did not have enough evidence to recommend a specific step target, the study authors note. That left 10,000 steps as the public's holy grail—even as many people fell short. The large number of studies published in the past decade finally provided enough data to inform a broad step target. One study in 2023 that researchers included in their analysis, for example, found as few as 2,800 steps reduced the risk of cardiovascular disease, with the most benefits at 7,200. The reviewers did find that 10,000 steps are associated with even lower risks for a few conditions, such as cancer mortality, dementia, and depressive symptoms. But the incremental improvement above the 7,000 was small. For most other health metrics, including type 2 diabetes prevention, the extra 3,000 steps yielded no additional gains. Still, '10,000 steps may remain a viable target for people who are more active,' the study states. (Walking is great for your health. Walking backward? Even better.) Don't wait--walk The researchers reviewed results from 57 studies involving 35 groups of people. The studies involved participants from the United States, U.K., Japan, Australia, and several other countries. Some involved older adults or people who already had chronic conditions or increased risk factors, but many were conducted on healthy young adults. The majority of studies assessed deaths from all causes as well as cardiovascular disease incidence and mortality—areas where walking has long been known to offer protection. Other conditions, including cancer, type two diabetes, cognitive outcomes, mental health, and falls, were examined by a range of four to six studies. The researchers acknowledge that the small number of studies for certain conditions is a limiting factor of the review. 'Some outcomes have more data than others. As we start to accumulate more data and studies, these results may be updated in the future,' Ding says. In addition, the researchers acknowledge that walking speed likely plays a role in the health outcomes they uncovered, but they were unable to precisely determine its effect or what an ideal pace might be. Still, the confirmation that walking just 7,000 steps a day can help stave off chronic conditions, including dementia, is music to ears of many physicians. 'Aerobic exercise has consistently been shown to be one of the most robust ways to prevent and delay dementia,' says Stephanie Towns, a neuropsychologist at the Yale School of Medicine, who says mechanisms likely include increasing the flow of oxygen and nutrients to the brain as well as controlling major risk factors like hypertension. 'I personally recommend to all my patients that one of the best ways to reduce dementia risk is regularly engaging in brisk walks,' she says. Or as Ding puts it, 'definitely don't wait' for more data to accrue. Lace up your walking shoes and get active now.
Yahoo
an hour ago
- Yahoo
Homesafe Launches Debt-Free Equity Release Amid Rising Living Costs
SYDNEY, AU / / July 23, 2025 / Homesafe Wealth Release , an Australian financial services company, has just announced the public launch of its Homesafe Wealth Release® product, responding to rising inflation and the escalating pressures of the cost of living on retirees. Homesafe Wealth Release® has been designed to help retired homeowners gain debt-free access to their home equity. "Many older Australians have built significant equity in their homes but don't want to take on more debt or be forced to sell and move," according to Dianne Shepherd, Homesafe's Managing Director. Key Features Applying a unique profit-sharing model to the problem, Homesafe's product grants homeowners a single lump-sum payment in return for an agreed-upon, capped share of the proceeds from the future sale of the home. With no debt involved, financially burdened retirees don't need to worry about interest or monthly repayments. They also retain home ownership and occupancy rights. They don't need to downsize, and they are protected against negative equity. Rather than take on the stress of a reverse mortgage loan, the retiree sells Homesafe a share of the home's future sale value. The size of that share helps determine how much of a lump-sum payment is available. Homesafe considers the share of future value, the home's current value, and the applicant's age when determining the amount of cash to offer in exchange for the share. Homeowners can access their equity flexibly by offering a smaller or larger share of the home's eventual value. Amounts that homeowners can access range between $25,000 and $1,000,000. Stability and Transparency Due to the long-term nature of the agreement involved, homeowners may have a high threshold for the stability they expect from a company like Homeshare. Meanwhile, Homesafe has been working to build its reputation for ethical practices, financial transparency, and strong consumer protections. Its website features real-life video testimonials from retirees who have successfully unlocked debt-free home equity through their agreements with Homesafe. Rhona, one of the retirees featured, expresses her delight at being able to stay in a home she has treasured for almost thirty years with its "lovely garden," while still being able to access funds that give her and her family the freedom to purchase a new family vehicle and make further improvements to the home. "Homesafe has given us peace of mind for the future," Rhona shares. Hank, another retiree, speaks of Homesafe's transparency throughout the process. "They didn't muck about with words; there were no parts to the documentation that were unclear," he shares. "It really made it so that we had nothing to be concerned about." Eligibility Homesafe currently offers coverage in 90% of Melbourne and Sydney postcodes and is available to homeowners who are at least 60 years old in Victoria and New South Wales but regions are believed to be expanding. To be eligible, the home must be debt-free, and all permanent residents in the house must be listed as homeowners on the title or have an interest in it. The home must also be the homeowners' principal residence. Website URL - name - Homesafe Solutions P/LEmail address - info@ - Sydney, SOURCE: Homesafe Solutions P/L View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
an hour ago
- UPI
Mercury preservative to be removed from all flu shots, CDC says
A nurse gives an influenza virus vaccine shot to a man at a Giant Pharmacy in Fairfax, Va., on Oct. 13, 2004. File Photo by Roger L. Wollenberg/UPI | License Photo July 23 (UPI) -- The mercury-based preservative thimerosal will be removed from all flu shots distributed in the United States, Health and Human Services Director Robert F. Kennedy Jr. said Wednesday. Kennedy made the change when he signed policies from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, according to a news release Wednesday. The committee voted 5-1 with one abstention for the changes at its meeting on June 25 and 26 in Atlanta. All people, including children, who receive a single dose of influenza will have them without mercury. Kennedy, who hasn't acted on other panel recommendations from June, signed the decision instead of the leader of the CDC. Susan Monarez, who is President Donald Trump's nominee to head the agency, hasn't been confirmed by the U.S. Senate. The committee also voted 6-0 to recommend all Americans age 6 months and older to receive an annual influenza vaccine. Flu vaccines are reformulated yearly because viruses mutate and evolve. Thimerosol was added to vials of vaccine that contain more than one dose to prevent the growth of germs, including bacteria and fungi. It was removed from children's vaccines in the United States in 2001. "After more than two decades of delay, this action fulfills a long-overdue promise to protect our most vulnerable populations from unnecessary mercury exposure," Kennedy said in a statement. "Injecting any amount of mercury into children when safe, mercury-free alternatives exist defies common sense and public health responsibility. Today, we put safety first." In 1999, the U.S. Public Health Service, the American Academy of Pediatrics and vaccine manufacturers agreed that any potential risk from mercury warranted removal as soon as possible. The advisory panel didn't act until Kennedy appointed new members in June to approve the changes, which was recommended by the European Medicines Agency in 2004. The eight committee members include some vaccine skeptics and pandemic response critics. The panel heard a presentation against thimerosal from Lyn Redwood, the former leader of Children's Health Defense, an anti-vaccine group founded by Kennedy. Redwood is listed as an "expert" on the HHS employee website. In the news release, vaccine manufacturers said they have the capacity to fill vials without mercury. "With the U.S. now removing mercury from all vaccines, we urge global health authorities to follow this prudent example for the protection of children worldwide," Kennedy said. The removal affects 4% to 5% of the flu vaccine supply in the U.S., CNBC reported. Multi-doses from Sanofi's Fluzone and two shots from CSL Sequirus included thimerosal. The other flu shots were free from it, according to the CDC. "We acknowledge the recommendation of the new Advisory Committee on Immunization Practices (ACIP)," Sanofi said in a statement to The Hill. "We will have sufficient supply of Sanofi flu vaccine to support customer preference for this season." The most common side effects from thimerosal in vaccines were red and swelling at the injection site with some people allergic to it, according to the CDC. In a book by Kennedy in 2014, he wrote thimerosal was "toxic to brain tissue" and likely caused autism. A 2010 CDC study found "that prenatal and infant exposure to vaccines and immunoglobulins that contain thimerosal does not increase risk for autism spectrum disorder." In all, more than 40 studies over several decades showed no connection between thimerosol and developmental delays. Flu shots for the 2025-2026 flu season are available starting in August.
